Additional Resources

New data regarding the prevention, diagnosis, and management of COVID-19 are emerging daily. Please see the list of resources provided below for additional up-to-date and comprehensive information on COVID-19.

Resources from the CDC, NIH, and WHO

National Institutes of Health (NIH). COVID-19 Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/introduction/.

Centers for Disease Control and Prevention (CDC). Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html.

CDC. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html

NIH. COVID-19 Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/introduction/

CDC. Information for Healthcare Professionals about Coronavirus (COVID-19). https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html

World Health Organization (WHO). Country & Technical Guidance – Coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance

Additional Guidance on the Management of Patients with COVID-19.

Society of Critical Care Medicine. Surviving Sepsis Campaign: COVID-19 Guidelines. https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19

Infectious Disease Society of America (IDSA). COVID-19 Resource Center. https://www.idsociety.org/public-health/COVID-19-Resource-Center/

IDSA. Infectious Diseases Society of America Guidelines on Infection Prevention in Patients with Suspected or Known COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-infection-prevention/

Recommendations on the Management of Special Populations During the COVID-19 Pandemic.

Al-Shamsi HO, Alhazzani W, Alhuraiji A, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. Oncologist. 2020. https://doi.org/10.1634/theoncologist.2020-0213.

American College of Surgeons (ACS). Recommendations for prioritization, treatment and triage of breast cancer patients during the COVID-19 pandemic. Available at https://www.facs.org/quality-programs/cancer/executive-summary.

American Society of Clinical Oncology (ASCO). COVID-19 Patient Care Information. https://www.asco.org/asco-coronavirus-information/care-individuals-cancer-during-covid-19

Centers for Disease Control and Prevention (CDC). Considerations for Inpatient Obstetric Healthcare Settings. https://www.cdc.gov/coronavirus/2019-ncov/hcp/inpatient-obstetric-healthcare-guidance.html

American College of Obstetricians and Gynecologists (ACOG). Novel Coronavirus 2019 (COVID-19). https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/03/novel-coronavirus-2019

Copyright © 2020 | COVID Frontline | All Rights Reserved | Website by Divigner

Patient Toolkit

The COVID FRONTLINE Patient Toolkit is a resource center for patients who have been diagnosed with or who are interested in learning about COVID-19. Choose from the options below to learn more.

Clinical Toolkit

The COVID-19 Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for COVID-19. Click on one of the options below to learn more.

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Merck & Co., Inc., and Pfizer.

Copyright © 2019 | COVID Frontline | All Rights Reserved | Website by Divigner

Updates in the Treatment and Prevention of COVID-19​

Emergency use authorization for casirivimab/imdevimab in patients with mild-to-moderate COVID-19

The combination of the monoclonal antibodies casirivimab and imdevimab (previously known as REGN-COV2) has been authorized for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (≥12 years of age and ≥40 kg) who are at high risk for progressing to severe COVID-19 or hospitalization.1

Interim results from 275 nonhospitalized patients in a placebo-controlled trial of casirivimab plus imdevimab found that the combination therapy reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Patients who received casirivimab/imdevimab required fewer medical visits for COVID-19 than patients who received placebo (3% vs 6%, respectively). Among patients who were serum antibody-negative at baseline, 15% in the placebo group and 6% in the treatment group required COVID-19-related medical care.2 

Baricitinib in combination with remdesivir authorized for emergency use in hospitalized patients

Baricitinib, in combination with remdesivir, is authorized for emergency use in adult and pediatric patients ≥2 years of age hospitalized for COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).3

A recent trial of 1033 patients hospitalized for COVID-19 found that baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time (7 days vs 8 days, respectively; P= .03). Patients receiving high-flow oxygen or noninvasive ventilation at enrollment had a time to recovery of 10 days with combination therapy and 18 days with the control (rate ratio for recovery, 1.51). The addition of baricitinib to remdesivir was associated with 30% higher odds of improvement in clinical status at day 15 compared with remdesivir alone.4 

 

References 

  1. Emergency use authorization (EUA) of casirivimab and imdevimab. Available at fda.gov/media/143892/download Accessed 12/23/2020.
  2. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2020;Dec 17:Epub ahead of print. Available at nejm.org/doi/full/10.1056/NEJMoa2035002Accessed 12/23/2020.
  3. Emergency use authorization (EUA) of baricitinib. Available at fda.gov/media/143823/download Accessed 12/23/2020.
  4. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020;Dec 11:Epub ahead of print. Available at nejm.org/doi/full/10.1056/NEJMoa2031994 Accessed 12/23/2020.